SCHEDULE: Farallon Capital Entities Report 8% Stake in Liquidia Corporation

Farallon Capital and its affiliated entities, including various funds and managing members, have collectively reported beneficial ownership of 8% of Liquidia Corporation's common stock.

Summary

• Farallon Capital Partners, L.P. and its related funds (Farallon Funds) along with their general partners and individual managing members, collectively reported beneficial ownership of Liquidia Corporation's Common Stock.
• The aggregate amount beneficially owned by the Farallon Individual Reporting Persons (managing members/senior managing members) is 6,832,472 shares, representing 8% of the class.
• Farallon Partners, L.L.C., as the general partner for several Farallon Funds, reported beneficial ownership of 6,619,847 shares, equating to 7.7% of the class.
• Specific Farallon Funds hold varying percentages of Liquidia shares, including Farallon Healthcare Partners Master, L.P. with 2,601,710 shares (3%), Farallon Capital Offshore Investors II, L.P. with 1,739,892 shares (2%), and Farallon Capital Partners, L.P. with 785,702 shares (0.9%).
• The filing is a Schedule 13G, indicating that the shares were not acquired or held for the purpose of changing or influencing the control of Liquidia Corporation.

Sentiment

Score: 5

Explanation: The document is a factual report of beneficial ownership, providing no positive or negative operational or financial news. The sentiment is neutral.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investment in Liquidia Corporation, a common occurrence in the biotechnology and healthcare sectors where specialized funds often take positions in promising companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Farallon Capital may be viewed positively by some investors as a vote of confidence, potentially influencing market perception and liquidity.

Key Dates

Keywords

Liquidia Corporation, Farallon Capital, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Healthcare, Biotechnology